E
Emily Ricotta
Researcher at National Institutes of Health
Publications - 48
Citations - 1658
Emily Ricotta is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 16, co-authored 38 publications receiving 724 citations. Previous affiliations of Emily Ricotta include Swiss Tropical and Public Health Institute & Johns Hopkins Center for Communication Programs.
Papers
More filters
Journal ArticleDOI
Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents.
Sameer S Kadri,Sameer S Kadri,Jennifer Adjemian,Jennifer Adjemian,Yi Ling Lai,Alicen B Spaulding,Emily Ricotta,D. Rebecca Prevots,Tara N. Palmore,Chanu Rhee,Chanu Rhee,Michael Klompas,Michael Klompas,John P. Dekker,John H. Powers,Anthony F. Suffredini,David C. Hooper,Scott K. Fridkin,Robert L. Danner +18 more
TL;DR: Nonsusceptibility to first-line antibiotics is associated with decreased survival in GNBSIs and DTR is a simple bedside prognostic measure of treatment-limiting coresistance.
Journal ArticleDOI
An immune-based biomarker signature is associated with mortality in COVID-19 patients.
Michael S. Abers,Ottavia M. Delmonte,Emily Ricotta,Jonathan Fintzi,Danielle Fink,Adriana Almeida de Jesus,Kol A. Zarember,Sara Alehashemi,Vasileios Oikonomou,Jigar V. Desai,Scott W. Canna,Bita Shakoory,Kerry Dobbs,Luisa Imberti,Alessandra Sottini,Eugenia Quiros-Roldan,Francesco Castelli,Camillo Rossi,Duilio Brugnoni,Andrea Biondi,Laura Rachele Bettini,Mariella D'Angiò,Paolo Bonfanti,Riccardo Castagnoli,Daniela Montagna,Amelia Licari,Gian Luigi Marseglia,Emily F. Gliniewicz,Elana Shaw,Dana Kahle,Andre Rastegar,Michael Stack,Katherine Myint-Hpu,Susan L Levinson,Mark J. DiNubile,Daniel W. Chertow,Peter D. Burbelo,Jeffrey I. Cohen,Katherine R. Calvo,John S. Tsang,Helen C. Su,John I. Gallin,Douglas B. Kuhns,Raphaela Goldbach-Mansky,Michail S. Lionakis,Luigi D. Notarangelo +45 more
TL;DR: Levels of sST2, sTNFRSF1A, IL-10, and IL-15 were consistently higher throughout the hospitalization in patients who died versus those who recovered, suggesting that these biomarkers may provide an early warning of eventual disease outcome.
Journal ArticleDOI
Association Between Caseload Surge and COVID-19 Survival in 558 U.S. Hospitals, March to August 2020.
Sameer S Kadri,Junfeng Sun,Alexander Lawandi,Jeffrey R. Strich,Lindsay M Busch,Michael J. Keller,Ahmed Babiker,Christina Yek,Seidu Malik,Janell Krack,John P. Dekker,Alicen B Spaulding,Emily Ricotta,John H. Powers,Chanu Rhee,Michael Klompas,Janhavi Athale,Tegan K. Boehmer,Adi V. Gundlapalli,William Bentley,S. Deblina Datta,Robert L. Danner,Cumhur Y Demirkale,Sarah Warner +23 more
TL;DR: In this article, the authors determined the association between hospitals' severity-weighted COVID-19 caseload and mortality risk and identified effect modifiers of this relationship, and the effect of surge index on risk-adjusted odds ratio (aOR) of in-hospital mortality or discharge to hospice was calculated using hierarchical modeling.
Journal ArticleDOI
Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model.
Kyle Rosenke,Frederick Hansen,Benjamin Schwarz,Friederike Feldmann,Elaine Haddock,Rebecca Rosenke,Kent D. Barbian,Kimberly Meade-White,Atsushi Okumura,Shanna Leventhal,David W Hawman,Emily Ricotta,Catharine M. Bosio,Craig Martens,Greg Saturday,Heinz Feldmann,Michael A. Jarvis,Michael A. Jarvis +17 more
TL;DR: In this paper, an orally administered nucleoside analog, MK-4482, inhibited SARS-CoV-2 replication in the Syrian hamster model, and the inhibitory effect was observed in animals when the drug was administered either beginning 12 hours before or 12 hours following infection in a high risk exposure model.
Journal ArticleDOI
Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals.
Sameer S Kadri,Sameer S Kadri,Yi Ling Lai,Sarah Warner,Jeffrey R Strich,Jeffrey R Strich,Ahmed Babiker,Emily Ricotta,Cumhur Y Demirkale,John P. Dekker,Tara N. Palmore,Chanu Rhee,Chanu Rhee,Michael Klompas,Michael Klompas,David C. Hooper,John H. Powers,Arjun Srinivasan,Robert L. Danner,Jennifer Adjemian,Jennifer Adjemian +20 more
TL;DR: Receiving discordant empirical antibiotic therapy was associated with increased odds of mortality overall, even in patients without sepsis, and was closely associated with infection with antibiotic-resistant pathogens.